US 11572408
Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
granted A61KA61K2039/505A61K31/4406
Quick answer
US patent 11572408 (Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent) held by VACCINEX, INC. expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K31/4406, A61K31/706, A61K31/7068